Survivin expression induced by doxorubicin in cholangiocarcinoma

Table 1 Correlation between clinicopathological factors and survivin expression in cholangiocarcinoma

Clinical features	n	Survivin expression		χ2	P
		n	%
All patients	33	24	72.7
Age (years)
60	18	13	72.2	0.0051	0.9431
≤ 60	15	11	73.5
Sex
Male	21	15	71.4	0.0491	0.8246
Female	12	9	75.0
Tumor size (cm)
≤ 2	13	10	76.9	0.1904	0.6626
> 2	20	14	70.6
Differentiation level
High & Middle	29	21	72.4	0.0119	0.9133
Low	4	3	75.0
Metastasis
Positive	7	5	71.4	0.0076	0.9307
Negative	26	19	73.1

Table 2 Expression level of survivin mRNA

Group	n	Survivin/β-actin	t	P
A	7	0.4210 ± 0.0551	bt = 45.89, dt = 12.54	bP, dP < 0.001
B	7	0.8481 ± 0.0713	bt = 26.11	bP < 0.001
C	7	1.7034 ± 0.0493

Survivin mRNA expression level was determined by survivin/β-actin protein. Data were expressed as mean ± SD, b vs C (48 h after adding doxorubicin), d vs B (24 h after adding doxorubicin), A: Normal Qbc939.

Table 3 Expression level of survivin protein

Group	n	OD value	t	P
A	6	204.568 ± 1.387	bt = 17.99, dt = 11.23	bP, dP < 0.001
B	6	311.105 ± 1.539	bt = 11.02	bP < 0.001
C	6	339.989 ± 1.872

Data were expressed as mean ± SD, b vs C (48 h after adding doxorubicin), d vs B (24 h after adding doxorubicin), A: Normal Qbc939.